DGAP-News: Neovacs S.A. / Key word(s): Conference
NEOVACS TO PRESENT AT CHINA BIO PARTNERING FORUM
14.04.2015 / 08:00
---------------------------------------------------------------------
PRESS RELEASE
NEOVACS TO PRESENT AT CHINA BIO PARTNERING FORUM
Company to Highlight Active Immunotherapy Platform Focused on Autoimmune
Diseases
Paris and Boston, April 14, 2015 - NEOVACS (Alternext Paris: ALNEV), a
leader in active immunotherapies for the treatment of autoimmune diseases,
announced today that is has been selected to present at the seventh annual
ChinaBio(R) Partnering Forum 2015 to be held in Shanghai, April 15 and 16,
2015.
This life science industry event is expected to attract over 800 attendees
from around the world focused on partnering opportunities and cross-border
relationships in China.
Miguel Sieler, CEO of Neovacs, will present recent information on Neovacs'
proprietary active immunotherapy platform on April 15, 2015 at 2:30 pm CST
(China Standard Time). China has a high prevalence of Systemic Lupus
Erythematosus (SLE) or lupus, an autoimmune disease characterized by a
significant unmet medical need. Several Chinese pharmaceutical companies
have shown interest in the potential for an innovative, affordable
biological treatment option, such as Neovacs' lead product candidate,
IFNα-Kinoid.
About ChinaBio(R) Partnering Forum
ChinaBio(R) Partnering Forum is the premier life science partnering event
in China. Held on April 15-16, 2015, in Shanghai, the event will attract
over 800 biotech and pharma leaders from around the world along with
hundreds of China-based developers of novel technologies for two days of
productive partnering. There will also be over 30 speakers and 50
companies participating in panels and workshops as well as one-to-one
partnering meetings held throughout the event.
About Neovacs
Created in 1993, Neovacs is today a leading biotechnology company focused
on an active immunotherapy technology platform (Kinoids) with applications
in autoimmune and/or inflammatory diseases. On the basis of the company's
proprietary technology for inducing a polyclonal immune response (covered
by five patent families that potentially run until 2032) Neovacs is
focusing its clinical development efforts on IFNα-Kinoid, an immunotherapy
being developed for the indication of lupus. Neovacs is also conducting
preclinical development works on other therapeutic vaccines in the fields
of auto-immune diseases, oncology and allergies. The goal of the Kinoid
approach is to enable patients to have access to safe treatments with
efficacy that is sustained in these life-long diseases.
For more information on Neovacs, please visit www.neovacs.fr.
Contacts
ChinaBio(R) Group
Jean Meng
China: +86 21 5137 0751
USA: +1 858 926 4566
jean.meng@chinabio.com
NEOVACS - Investor Relations
Nathalie Trépo
+33 (0)1 53 10 93 00
ntrepo@neovacs.com
Investor Relations / Financial Communications - NewCap
Valentine Brouchot / Pierre Laurent
+33 (0)1 44 71 94 94
theradiag@newcap.fr
Investor Relations / Financial Communications Germany - MC Services
Raimund Gabriel
+49-89-210228-30
raimund.gabriel@mc-services.eu
Press / U.S. Inquiries - The Ruth Group
Melanie Sollid-Penton
1.646.536.7023
msollid@theruthgroup.com
---------------------------------------------------------------------
14.04.2015 Dissemination of a Corporate News, transmitted by DGAP - a
service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------
Language: English
Company: Neovacs S.A.
3-5, Impasse Reille
75014 Paris
France
Phone: +33 (0)1 53 10 93 00
Fax: +33 (0)1 53 10 93 03
E-mail: www.neovacs.fr
Internet: info@neovacs.fr
ISIN: FR0004032746
WKN: A1CVKR
Listed: Regulated Unofficial Market in Stuttgart; Open Market in
Frankfurt
End of News DGAP News-Service
---------------------------------------------------------------------
343691 14.04.2015
DGAP-News: NEOVACS TO PRESENT AT CHINA BIO PARTNERING FORUM
| Source: EQS Group AG